LOGIN
Greater BMD increase with denosumab vs ZOL in patients switching from oral bisphosponates
January 2017
Greater BMD increase with denosumab vs ZOL in patients switching from oral bisphosponates
Study Type:Therapy
OE Level Evidence:1
Journal Level of Evidence:N/A
Denosumab or Zoledronic Acid in Postmenopausal Women With Osteoporosis Previously Treated With Oral Bisphosphonates
J Clin Endocrinol Metab. 2016 Aug;101(8):3163-70Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here
Synopsis
643 postmenopausal women with osteoporosis who had used oral bisphosphonate for a minimum of 2 years were randomized to either subcutaneous injections of denosumab 60mg - one at baseline and another at 6 months - or intravenous injection of zoledronic acid 5mg. The purpose of this study was to evaluate if denosumab offered noninferior or superior efficacy and safety to zoledronic acid for increasi...
To view the full content, login to your account,
or start your 30-day FREE Trial today.
FREE TRIAL
LOGIN
Forgot Password?
Explore some of our unlocked ACE Reports below!
Join the Conversation
Please Login or Join to leave comments.